DJS Antibodies
Christopher Lynch is a Senior Scientist II specializing in Antibody and Protein Biochemistry at DJS Antibodies since June 2023. Prior experience includes roles as Scientist II and Associate Scientist in Protein Engineering at MiroBio Ltd from February 2020 to June 2023, and a Postdoctoral position at the University of Oxford from June 2017 to February 2020. Christopher also completed a Ph.D. at Imperial College London, where additionally served as a Research Assistant from December 2011 to May 2017. Earlier experience includes working as a Scientific Officer at The Institute of Cancer Research from February 2010 to December 2011, and a Bachelor of Science in Biochemistry from the University of Essex, obtained in 2009.
DJS Antibodies
1 followers
DJS Antibodies is developing novel therapeutics to treat chronic inflammatory diseases. DJS does this through the discovery and development of novel therapeutic monoclonal antibodies against GPCRs. The company's breakthrough technology enables its to produce first-in-class antibody therapeutics to previously intractable disease targets.